Last reviewed · How we verify
[14C]-TAK-385 Oral Solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-TAK-385 Oral Solution ([14C]-TAK-385 Oral Solution) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-TAK-385 Oral Solution TARGET | [14C]-TAK-385 Oral Solution | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-TAK-385 Oral Solution CI watch — RSS
- [14C]-TAK-385 Oral Solution CI watch — Atom
- [14C]-TAK-385 Oral Solution CI watch — JSON
- [14C]-TAK-385 Oral Solution alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-TAK-385 Oral Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-tak-385-oral-solution. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab